Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREACH-TB
PACTR202604471407334Phase 3Not yet recruiting
- Sponsor
- Johns Hopkins University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3 trial of bedaquiline, rifapentine, isoniazid and levofloxacin in Tuberculosis (TB) and latent tuberculosis infection (LTBI) (3 arms), sponsored by Johns Hopkins University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
bedaquilinerifapentineisoniazidlevofloxacin
03
Conditions
Tuberculosis (TB)latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on PACTR202604471407334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202604471407334.